August 28, 2023. SGLT-2 Inhibitors Lowers the Risk of Progression of CKD or Cardiovascular Death in Patients with CKD

Article name: Empagliflozin in Patients with Chronic Kidney Disease

Link
DOI

This article was published in the New England Journal of Medicine in 2023. It is a randomized controlled trial which compared the use of an SGLT-2 inhibitor (empaglifozin) against placebo. The endpoint was progression of chronic kidney disease (CKD) or cardiovascular death.

In the empaglifozin group, after 2 years, 13.1% of the group reached the endpoint. In the placebo group, 16.9% reached the endpoint (hazard ratio, 0.72; 95% confidence interval [CI], 0.64 to 0.82; P<0.001). The results were consistent amongst various subgroups including diabetics and non diabetics.

Any information or statement present in this post does not replace your health care provider’s advice or treatment. This blog does not provide medical advice, prescribe medications or therapies, or diagnose conditions, it only expresses an opinion. If you have a health-related question or condition, confer with your healthcare provider.